不同甲型H7N9流感疫苗方案抗神经氨酸酶与抗血凝素茎部应答
该研究在系列临床试验中测定疫苗神经氨酸酶含量,并证明接种两剂AS03佐剂甲型H7N9灭活疫苗后神经氨酸酶抑制抗体应答呈剂量依赖性升高,延长两剂间隔或5年后延迟加强也可提高该应答,而同期或序贯接种季节性流感疫苗及使用异源H7N9疫苗影响不大;抗血凝素茎部抗体应答微弱且不持久。
要点
- 两剂AS03佐剂甲型H7N9灭活疫苗后神经氨酸酶抑制抗体应答呈剂量依赖性升高。
- 延长两剂间隔或5年后异源佐剂疫苗延迟加强可提高神经氨酸酶抑制抗体应答。
- 同期或序贯季节性流感疫苗及异源H7N9疫苗对神经氨酸酶抑制抗体应答无明显影响。
核心结论
- 研究提供证据支持可进一步标准化用于大流行防范的改善抗神经氨酸酶应答策略。
研究设计与样本
- 系列临床试验,测定疫苗神经氨酸酶含量并评估不同甲型H7N9灭活疫苗方案的抗体应答。
主要发现
- 两剂AS03佐剂甲型H7N9灭活疫苗初免后神经氨酸酶抑制抗体应答呈剂量依赖性升高。
- 延长两剂初免间隔或5年后异源佐剂甲型H7N9灭活疫苗延迟加强后神经氨酸酶抑制抗体应答升高。
- 同期或序贯季节性流感疫苗接种及两剂初免中使用异源甲型H7N9灭活疫苗对神经氨酸酶抑制抗体应答无明显影响。
- 抗血凝素茎部抗体应答微弱且不持久。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pandemic influenza vaccine development focuses on the hemagglutinin (HA) antigen for potency and immunogenicity. Antibody responses targeting the neuraminidase (NA) antigen, or the HA stalk domain have been implicated in protection against influenza. Responses to the NA and HA-stalk domain following pandemic inactivated influenza are not well characterized in humans. MATERIAL AND METHODS: In a series of clinical trials, we determine the vaccines' NA content and demonstrate that NA inhibition (NAI) antibody responses increase in a dose-dependent manner following a 2-dose priming series with AS03-adjuvanted influenza A(H7N9) inactivated vaccine (A(H7N9) IIV). NAI antibody responses also increase with interval extension of the 2-dose priming series or following a 5-year delayed boost with a heterologous adjuvanted A(H7N9) IIV. Neither concomitant seasonal influenza vaccination given simultaneously or sequentially, nor use of heterologous A(H7N9) IIVs in the 2-dose priming series had an appreciable effect on NAI antibody responses. Anti-HA stalk antibody responses were minimal and not durable. CONCLUSIONS: We provide evidence for strategies to improve anti-neuraminidase responses which can be further standardized for pandemic preparedness. CLINICAL TRIAL REGISTRY NUMBERS: NCT03312231, NCT03318315, NCT03589807, NCT03738241.
引用
- El Sahly HM, Anderson EJ, Jackson LA, et al. Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens. Vaccine. 2025. PMID: 39756216. doi:10.1016/j.vaccine.2024.126689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。